| Preface |
|
v | |
| Contributors |
|
xi | |
|
|
|
|
1 Multiplex Technologies in COVID-19 Research, Diagnostics, and Prognostics: Battling the Pandemic |
|
|
3 | (18) |
|
|
|
|
|
|
|
|
|
|
|
2 Multivalent Vaccine Strategies in Battling the Emergence of COVID-19 Variants |
|
|
21 | (16) |
|
|
|
3 Challenges of Multiplex Assays for COVID-19 Research: A Machine Learning Perspective |
|
|
37 | (16) |
|
|
|
|
|
|
|
|
|
|
4 Multiplex Quantitative Polymerase Chain Reaction Diagnostic Test for SARS-CoV-2 and Influenza A/B Viruses |
|
|
53 | (14) |
|
|
|
|
|
5 Multiplex Quantitative Polymerase Chain Reaction Test to Identify SARS-CoV-2 Variants |
|
|
67 | (12) |
|
|
|
|
|
6 NIRVANA for Simultaneous Detection and Mutation Surveillance of SARS-CoV-2 and Co-infections of Multiple Respiratory Viruses |
|
|
79 | (10) |
|
|
|
|
|
|
|
7 Quantitative Real-Time RT-PCR Systems to Detect SARS-CoV-2 |
|
|
89 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8 Guidance for SARS-CoV-2 RNA-Based Molecular Assay Analytical Performance Evaluations |
|
|
99 | (18) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9 A Rapid User-Friendly Lab-on-a-Chip Microarray Platform for Detection of SARS-CoV-2 Variants |
|
|
117 | (16) |
|
|
|
|
|
|
|
10 SARS-CoV-2 Host Immunogenetic Biomarkers |
|
|
133 | (16) |
|
|
|
|
|
|
|
|
|
11 FnCas9 Editor Linked Uniform Detection Assay for COVID-19 |
|
|
149 | (12) |
|
|
|
|
|
|
|
|
|
|
|
12 Mass Spectrometry Multiplexed Detection of SARS-CoV-2 |
|
|
161 | (14) |
|
|
|
|
|
|
|
|
|
|
|
Karina Helena Morals Cardozo |
|
|
Valdemir Melechco Carvalho |
|
|
13 Identification of Circulating Biomarkers of COVID-19 Using MALDI-TOF Mass Spectrometry |
|
|
175 | (8) |
|
|
|
|
|
|
|
14 Antibody-Based Affinity Capture Combined with LC-MS Analysis for Identification of COVID-19 Disease Serum Biomarkers |
|
|
183 | (18) |
|
|
|
|
|
15 Liquid Chromatography-Mass Spectrometry Analysis of Peripheral Blood Mononuclear Cells from SARS-CoV-2 Infected Patients |
|
|
201 | (12) |
|
|
|
|
|
16 Assay of Fatty Acids and Their Role in the Prevention and Treatment of COVID-19 |
|
|
213 | (22) |
|
|
|
|
|
|
|
|
|
17 Lab-on-a-Chip Immunoassay for Prediction of Severe COVID-19 Disease |
|
|
235 | (10) |
|
|
|
|
|
|
|
|
|
18 Multiplex Immunoassay for Prediction of Disease Severity Associated with the Cytokine Storm in COVID-19 Cases |
|
|
245 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
19 Detection of IgG Antibodies to SARS-CoV-2 and Neutralizing Capabilities Using the Luminex® xMAP® SARS-CoV-2 Multi-Antigen IgG Assay |
|
|
257 | (16) |
|
|
|
|
|
|
|
|
|
|
|
20 Multiplex Testing of the Effect of Statins on Disease Severity Risk in COVID-19 Cases |
|
|
273 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
21 Evaluating the Effects of Curcumin on the Cytokine Storm in COVID-19 Using a Chip-Based Multiplex Analysis |
|
|
285 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22 COVID-19 Detection Using the NHS Lateral Flow Test Kit |
|
|
297 | (10) |
|
|
|
|
|
23 Evaluation Protocol for SARS-CoV-2 Serological Assays |
|
|
307 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24 Measurement of Mitochondrial Respiration in Cryopreserved Human Peripheral Blood Mononuclear Cells (PBMCs) |
|
|
321 | (12) |
|
|
|
|
|
|
|
|
|
|
|
25 Multiplex Testing of Oxidative-Reductive Pathway in Patients with COVID-19 |
|
|
333 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
26 Point-of-Care Device for Assessment of Blood Coagulation Status in COVID-19 Patients |
|
|
345 | (10) |
|
|
|
|
|
27 COVID-19 and the Assessment of Coenzyme Q10 |
|
|
355 | (12) |
|
|
|
|
|
|
|
28 Isolation and Cell Culture of Human Nasopharyngeal Cells: A Model for Testing Immune Response and Antiviral Treatment |
|
|
367 | (8) |
|
|
|
Ana Paula Duarte de Souza |
|
|
29 Machine Learning Approaches to Analyze MALDI-TOF Mass Spectrometry Protein Profiles |
|
|
375 | (20) |
|
|
|
|
|
|
|
30 A Deep Learning Approach to Identify Chest Computed Tomography Features for Prediction of SARS-CoV-2 Infection Outcomes |
|
|
395 | (12) |
|
|
|
|
|
|
|
|
|
Mohamad Amin Pourhoseingholi |
|
|
|
|
|
|
|
|
Part III Future Perspectives |
|
|
|
31 Genomic Surveillance for Monitoring Variants of Concern: SARS-CoV-2 Delta, Omicron, and Beyond |
|
|
407 | (8) |
|
|
| Index |
|
415 | |
